245 related articles for article (PubMed ID: 32287321)
1. CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese cortisol-producing adrenocortical carcinoma with TP53 somatic variant.
Ikeya A; Nakashima M; Yamashita M; Kakizawa K; Okawa Y; Saitsu H; Sasaki S; Sasano H; Suda T; Oki Y
PLoS One; 2020; 15(4):e0231665. PubMed ID: 32287321
[TBL] [Abstract][Full Text] [Related]
2. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
[TBL] [Abstract][Full Text] [Related]
3. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
Fojo T; Huff L; Litman T; Im K; Edgerly M; Del Rivero J; Pittaluga S; Merino M; Bates SE; Dean M
BMC Med Genomics; 2020 Nov; 13(1):165. PubMed ID: 33148256
[TBL] [Abstract][Full Text] [Related]
4. Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma.
Heinze B; Herrmann LJ; Fassnacht M; Ronchi CL; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
Eur J Endocrinol; 2014 May; 170(5):707-17. PubMed ID: 24566897
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of TP53 alterations in adrenocortical carcinomas.
Waldmann J; Patsalis N; Fendrich V; Langer P; Saeger W; Chaloupka B; Ramaswamy A; Fassnacht M; Bartsch DK; Slater EP
Langenbecks Arch Surg; 2012 Feb; 397(2):209-16. PubMed ID: 22203015
[TBL] [Abstract][Full Text] [Related]
7. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
8. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
9. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
[TBL] [Abstract][Full Text] [Related]
10. Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series.
Creemers SG; Korpershoek E; Atmodimedjo PN; Dinjens WNM; van Koetsveld PM; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2017 Oct; 102(10):3611-3615. PubMed ID: 28973495
[TBL] [Abstract][Full Text] [Related]
11. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
Juhlin CC; Goh G; Healy JM; Fonseca AL; Scholl UI; Stenman A; Kunstman JW; Brown TC; Overton JD; Mane SM; Nelson-Williams C; Bäckdahl M; Suttorp AC; Haase M; Choi M; Schlessinger J; Rimm DL; Höög A; Prasad ML; Korah R; Larsson C; Lifton RP; Carling T
J Clin Endocrinol Metab; 2015 Mar; 100(3):E493-502. PubMed ID: 25490274
[TBL] [Abstract][Full Text] [Related]
13. Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma.
Akhavanfard S; Yehia L; Padmanabhan R; Reynolds JP; Ni Y; Eng C
Hum Mol Genet; 2021 Jan; 29(22):3679-3690. PubMed ID: 33326033
[TBL] [Abstract][Full Text] [Related]
14. A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma.
Bulzico D; Torres DC; Ferreira GM; Pires BRB; de Faria PAS; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
Endocr Pathol; 2017 Dec; 28(4):326-331. PubMed ID: 28421464
[TBL] [Abstract][Full Text] [Related]
15. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status.
Brenna CTA; Michaeli O; Wasserman JD; Malkin D
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e635-e641. PubMed ID: 33122580
[TBL] [Abstract][Full Text] [Related]
17. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
18. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract][Full Text] [Related]
19. A novel p.Gly187Arg TP53 variant appears to result in Li-Fraumeni syndrome.
Doyle MR; Johnston JM
Pediatr Hematol Oncol; 2018 Apr; 35(3):203-207. PubMed ID: 30239254
[TBL] [Abstract][Full Text] [Related]
20. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
